Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 333-341

  Driver, Kristy E ^a   Song, Honglin ^a   Lesueur, Fabienne ^a   Ahmed, Shahana ^a   Barbosa Morais, Nuno L ^b   Tyrer, Jonathan P ^a   Ponder, Bruce A J ^b   Easton, Douglas F ^a   Pharoahm, Paul D P ^c   Dunning, Alison M ^c   Abraham, Jean ^c   Antoniou, Antonis ^c   Baynes, Caroline ^c   Benusiglio, Patrick ^c   Blows, Fiona ^c   Cebrian, Arancha ^c   Conroy, Don ^c   Curzon, Bridget ^c   Dew, Gary ^c   Driver, Kristy ^c   Field, Helen ^c   Ghoussaini, Maya ^c   Harrington, Patricia ^c   Healey, Catherine ^c   Irvine, Sue ^c   Kalmyrzaev, Bolot ^c   Jordan, Clare ^c   Luccarini, Craig ^c   Mayes, Rebecca ^c   Maranian, Melanie ^c   Morrison, Jonathan ^c   Munday, Hannah ^c   Perkins, Barbara ^c   Pooley, Karen ^c   Redman, Karen ^c   Scollen, Serena ^c   Shadforth, Danielle ^c   Shah, Mitul ^c   Simpson, Anabel ^c   Thompson, Deborah ^c   Tyrer, Jonathan ^c   Smith, Paula ^c   West, Judy ^c   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CELL CYCLE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYTOSINE; GUANINE; NUCLEIC ACID BINDING PROTEIN; PROTEIN CCND1; PROTEIN CCND2; PROTEIN CCND3; PROTEIN CCNE1; THYMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADULT; AGED; BREAST NEOPLASMS; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 40549130341     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm284     Document Type: Article

References (49)

1. Lichtenstein,P. et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343, 78-85.
2. Antoniou,A.C. et al. (2006) Models of genetic susceptibility to breast cancer. Oncogene, 25, 5898-5905.
3. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br. J. Cancer, 83, 1301-1308.
4. CHEK2 Breast Cancer Case-Control Consortium. (2004) CHEK21100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet., 74, 1175-1182.
5. Cox,A. et al. (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet., 39, 352-358.
6. Erkko,H. et al. (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature, 446, 316-319.
7. Meijers-Heijboer,H. et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet., 31, 55-59.
8. Rahman,N. et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet., 39, 165-167.
9. Renwick,A. et al. (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet., 38, 873-875.
10. Seal,S. et al. (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet., 38, 1239-1241.
11. Thompson,D. et al. (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst., 97, 813-822.
12. Easton,D.F. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
13. Hunter,D.J. et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet, 39, 870-874.
14. Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447, 661-678.
15. Easton,D.F. et al. (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res., 1, 14-17.
16. Golias,C.H. et al. (2004) Cell proliferation and cell cycle control: a mini review. Int. J. Clin. Pract., 58, 1134-1141.
17. Bartek,J. et al. (2001) Cell cycle. Order from destruction. Science, 294, 66-67.
18. Malumbres,M. et al. (2001) To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer, 1, 222-231.
19. Park,M.T. et al. (2003) Cell cycle and cancer. J. Biochem. Mol. Biol., 36, 60-65
20. Li,G. et al. (2005) Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 26, 1596-1602.
21. Zheng,Y. et al. (2001) Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis, 22, 1195-1199.
22. Lukas,J. et al. (1997) WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am. J. Pathol., 150, 167-175.
23. Geradts,J. et al. (2000) Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod. Pathol., 13, 945-953.
24. Reed,W. et al. (1999) Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch., 435, 116-124.
25. Woloschak,M. et al. (1996) Frequent loss of the P16INK4a gene product in human pituitary tumors. Cancer Res., 56, 2493-2496.
26. Arber,N. et al. (1999) Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epidemiol. Biomarkers Prev., 8, 1101-1105.
27. Howard,A. et al. (1951) Synthesis of nucleoprotein in bean root cells. Nature, 167, 599-600.
28. Pardee,A.B. (1974) A restriction point for control of normal animal cell proliferation. Proc. Natl Acad. Sci. USA., 71, 1286-1290.
29. Lesueur,F. et al. (2006) Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population. Br. J. Cancer, 94, 1921-1926.
30. Ezhevsky,S.A. et al. (2001) Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol. Cell Biol., 21, 4773-4784.
31. Sherr,C.J. et al. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13, 1501-1512.
32. Baynes,C. et al. (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res., 9, R27.
33. Pe'er,I. et al. (2006) Evaluating and improving power in wholegenome association studies using fixed marker sets. Nat. Genet., 38, 663-667.
34. de Bakker,P.I. et al. (2005) Efficiency and power in genetic association studies. Nat. Genet., 37, 1217-1223.
35. Stram,D.O. et al. (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum. Hered., 55, 27-36.
36. Tyrer,J. et al. (2006) The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs. Genet. Epidemiol., 30, 636-643.
37. Freimer,N.B. et al. (2005) Guidelines for association studies in Human Molecular Genetics. Hum. Mol. Genet., 14, 2481-2483.
38. Pharoah,P.D. et al. (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet., 3, e42.
39. Ohtsubo,M. et al. (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell Biol., 15, 2612-2624.
40. Drake,J.A. et al. (2006) Conserved noncoding sequences are selectively constrained and not mutation cold spots. Nat. Genet., 38, 223-227.
41. Ortega,S. et al. (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta, 1602, 73-87.
42. Debniak,T. (2006) CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Res Treat, 103, 355-359.
43. Wang,S.S. et al. (2006) Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum. Genet., 120, 297-300.
44. Stamm,S. et al. (2005) Function of alternative splicing. Gene, 344, 1-20.
45. Stamm,S. et al. (2006) ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res., 34, D46-D55.
46. Kanopka,A. et al. (1996) Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA. Nature, 381, 535-538.
47. Simard,M.J. et al. (2002) SRp30c is a repressor of 3' splice site utilization. Mol. Cell Biol., 22, 4001-4010.
48. Ma,H. et al. (2006) Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int. J. Cancer, 119, 2173-2178.
49. Pharoah,P.D. et al. (2004) Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer, 4, 850-860.